A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs LYC 55716 (Primary)
- Indications Bladder cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ARGON
- Sponsors Lycera
- 16 Nov 2017 Planned number of patients changed from 90 to 105.
- 16 Nov 2017 Planned End Date changed from 1 Jun 2018 to 1 Mar 2019.
- 16 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2019.